Abstract: Understanding the mechanism of brain glucose transport across the blood-brain barrier is of importance to understanding brain energy metabolism. The specific kinetics of glucose transport have been generally described using standard Michaelis-Menten kinetics. These models predict that the steady-state glucose concentration approaches an upper limit in the human brain when plasma glucose is well above the Michaelis-Menten constant K t for half maximal transport. In experiments where steady-state plasma glucose was varied from 4 to 30 mM brain glucose was a linear function of plasma glucose concentration. At plasma concentrations nearing 30 mM brain glucose approached 9 mM, which was significantly higher than predicted from the previously reported K t of ~ 4mM (p<0.05). The high brain glucose concentration measured in the human brain suggests that ablumenal brain glucose concentrations may compete with lumenal glucose for transport. We developed a model based on a reversible Michaelis-Menten kinetic formulation of unidirectional transport rates. Fitting this model to brain glucose as a function of plasma glucose gave a substantially lower K t of 0.6±2.0mM, which was consistent with the previously reported millimolar K m of GLUT-1 in erythrocyte model systems. Previously reported and reanalyzed quantification provided consistent kinetic parameters. We conclude that cerebral glucose transport is most consistently described when using reversible Michaelis-Menten kinetics. Key Words: NMR---Glucose transport---in vivo studies---Spectroscopy---Human.
exclusively in most studies of the brain, for reviews see, e.g. (Gjedde, 1992; Lund-Andersen, 1979; Pardridge, 1983) , with one exception .
Many elegant techniques have been applied to study brain glucose uptake. The indicator-dilution techniques sample tracer extraction with a single pass across the capillary bed at a very high time resolution, but with a somewhat limited spatial resolution (Knudsen et al., 1990) . On the other hand, state-of-the art tracer techniques, such as positron emission tomography (PET), can provide a high spatial resolution (Svarer et al., 1996) . However, the information on cerebral glucose content is indirect since the active metabolism of labeled glucose implies substantial label accumulation in metabolic products which cannot be distinguished from native glucose. To overcome this limitation, glucose analogs that are not metabolized such as methylglucose have also been used (Brooks et al., 1986; Feinendegen et al., 1986) . Unfortunately, using glucose analogs has the disadvantage that the physical and apparent distribution volumes of the analog may not be identical to that of D-glucose. It has therefore become customary to relate the measurements to native glucose by using suitable conversion constants such as the lumped constant, which itself depends on precise knowledge of tissue glucose content (Reivich et al., 1985) . Cerebral glucose content is dictated by the transport capacity of the blood-brain barrier as well as the metabolic consumption.
Glucose transport across membranes is mediated by a family of transporter proteins (Mueckler, 1994) . The majority of evidence has suggested that the ubiquitous highaffinity transporter present in erythrocyte membranes, GLUT-1, is also the dominant transporter protein at the blood-brain barrier, with minor contributions from other transporters (Gerhart et al., 1992; Kalaria et al., 1988; Maher et al., 1993) . Inside the brain, a different transporter may be responsible for glucose transport across the cell membranes. However, several studies have suggested that the large surface area of brain cells may result in rapid equilibration inside the brain's aqueous phase leading to similar intra-and extracellular glucose concentrations (Gjedde, 1992; Gjedde & Diemer, 1983; Holden et al., 1991; Lund-Andersen, 1979; Silver & Erecinska, 1994; Whitesell et al., 1995) .
Since the transporter isoform at the blood-brain barrier and at the erythrocyte membrane are very similar, the kinetic constant for half-maximal transport, K t , should in principle be of similar magnitude. However, when reviewing the literature on animal brain glucose transport, a noticeable distribution of the measured brain K t was observed, ranging from 2mM to 14mM, as previously reviewed by (Gjedde, 1992; Mason et al., 1992) . Likewise, the reported K m for glucose transport varies in the erythrocyte from 0.5mM in the zero-trans entry experiments to the equilibrium exchange K m of 30mM (Carruthers, 1990) . Noteworthy is the observation that in the erythrocyte studies, which is a system of high purity and of great simplicity, the Michaelis-Menten constants also appear to diverge substantially. Some of the discrepancy has been attributed to methodological inadequacies and some may potentially be explained by differences in species-specific expression of GLUT-1 (Cloherty et al., 1996) .
Localized glucose transport kinetic measurements in human brain (Blomqvist et al., 1991; Brooks et al., 1986; Feinendegen et al., 1986; Gruetter et al., 1992a; Gruetter et al., 1996c) have so far been highly consistent with a Michaelis-Menten constant K t of 4-5 mM for transport and an average maximal transport rate T max of approximately 1µmol/g min, as reviewed by (Gjedde, 1992; Gruetter et al., 1996c) . These kinetic constants of the standard Michaelis-Menten model predicted that brain glucose should be below 5µmol/g when plasma glucose is below 30mM. However, the highest plasma glucose values previously examined was 13.5mM, where any potential discrepancy of the model may have been masked by experimental scatter. The purpose of the present study was to confirm the predicted relationship between plasma and brain glucose at very high plasma glucose concentrations. A preliminary report has appeared.
MATERIALS AND METHODS

Subjects
18 healthy human subjects were studied in 23 studies after giving informed consent according to procedures approved by the Institutional Review Board:Human subjects committee. At the time of study, the subjects were 41 ±13 years in age and weighed 67±11 kg. On the morning of study, subjects reported to the Center for Magnetic Resonance Research in the fasting state. In preparation for the clamp procedure, an intravenous catheter was placed antegrade in each forearm and retrograde in a foot. Extremities were warmed by placing preheated pads and water soaked towels around the lower extremities. Somatostatin was infused into one arm vein at a progressively increasing rate up to 0.16 µg/kg/min to suppress endogenous pancreatic insulin and glucagon secretion (Seaquist et al., 1994) . Dextrose (50% w/vol) was infused into the other arm vein at a variable rate adjusted to maintain target glycemia. Alterations in the glucose infusion rate were made based on the plasma glucose concentration measured on a nearby glucose analyzer (Beckman, Fullerton, CA) in blood samples taken from the foot vein every 3-5 minutes. Additional blood samples were obtained every 10 minutes for the later determination of plasma insulin concentration and both before and after the study for assessment of plasma ketone concentrations.
Chemical assays
Insulin was measured in serum that had been frozen within 30 minutes of acquisition using the double antibody method of Morgan and Lazarow (Morgan & Lazarow, 1963) .
Serum ketones were assessed in the clinical laboratory by a qualitative test based on the nitroferrocyanide reaction.
MRI
All experiments were performed in a 4 Tesla 125 cm bore magnet (Siemens/Varian). Subjects were positioned supine on the patient bed above the surface coil. After coil tuning, magnetic resonance imaging was acquired using either FLASH (Haase et al., 1986) or MDEFT (Lee et al., 1995) to determine localization for spectroscopy according to anatomical landmarks. Subjects wore earplugs to minimize gradient noise and were placed into the coil holder using cushions to minimize head movement. Shimming of the identified region-of-interest was performed using FASTMAP (Gruetter, 1993) , as described previously (Gruetter & Ugurbil, 1995) , which resulted in water linewidths of 7-9 Hz and metabolite linewidths of 5-8 Hz.
H MR spectroscopy
1 H MR spectroscopy was performed inside a 33cm head gradient providing 30mT/m gradient strengths. The rise time was controlled by software and set to 250µs. A 18cm triple surface coil arrangement producing quadrature polarization (Merkle et al., 1993) was used for excitation and reception. The 3,1-DRY-STEAM modification of the stimulated echo spectroscopy (STEAM), was used with an echo time TE of 20ms, TM=33ms and TR=3s as described previously, see (Gruetter et al., 1996b) and refs. therein. Water suppression was achieved by using 25 ms long Gaussian pulses at the water frequency one of which was applied during the 33 ms long TM period between the second and third slice selective pulses. Outer volume suppression in a plane adjacent to the volume at the coil surface was performed using BISTRO (deGraaf et al., 1995) . The selected volume size was 27 ml (3x3x3cm 3 ), which was confined to encompass the visual cortex, an area of consistently high metabolic activity and blood flow. The volume was placed symmetrically placed with respect to the brain midline and the large veins were excluded by the position. Unwanted coherences were eliminated by placing two 5 ms long crusher gradients (28.8 mT/m, 40 ms apart) in each TE period, which amounts to a diffusion weighting factor b=54 s/mm 2 , thereby reducing the vascular signal by approximately 40% (Neil et al., 1994) .
Spectra were obtained with a 1.5 min time resolution, which permitted retrospective summation of those time periods that followed a 20 minute stabilization in plasma glucose. Processing included extensive zero-filling, exponential multiplication corresponding to 2 Hz line broadening. Quantification of the glucose peak at 5.23 ppm was performed relative to the creatine (Cr) methyl resonance at 3.04 ppm as follows: To account for contributions of macromolecule resonances at 2.98 ppm, which are manifest in the 4 Tesla spectra as an upfield shoulder of the creatine peak, two Lorentzian peaks were fitted simultaneously at 3.04 ppm and at 2.98 ppm. The linewidth of the latter peak was set to the sum of 11Hz plus the linewidth of Cr. The glucose resonance was fitted to a Lorentzian curve whose linewidth was set to the Cr linewidth plus 2 Hz. Glucose concentration was calculated from the area of the glucose peak, I Glc , and the area of the Cr peak, I Cr , according to
where the concentration of the total Cr intensity, [Cr] tot , was set to 10mM, based on its cortical concentration of 9.6mM (Petroff et al., 1989 ) and on contributions of 1mM GABA in this region of the brain . The residual was visually inspected to verify proper convergence of the peak fitting routine, which is a standard part of the spectrometer software. The transverse relaxation times of glucose and creatine were assumed to be identical, based on our previously reported T 2 of at least 90ms (Gruetter et al., 1996b) and the similarity of the linewidth, when taking into account the contributions from J coupling. The saturation factors (due to the longitudinal relaxation times) were also assumed to be identical for both resonances, based on the observation that an inversion pulse applied before the beginning of the pulse sequence eliminates the glucose and the Cr resonance at the same inversion delay (not shown) and that the TR of 3 s is approximately 2.5 times the T 1 of Cr (Mason et al., 1994; Posse et al., 1995) .
C MRS
13 C MRS was performed on a 4 Tesla magnet using standard Siemens VISION body gradients, capable of providing 24mT/m in 1.2 ms using a quadrature 1 H coil (12 cm diameter) with a 7cm diameter 13 C coil (Adriany & Gruetter, 1997) . Localization was achieved with PRECISELY, which is a combination of ISIS localization (Ordidge et al., 1986) and DEPT polarization transfer methods (Doddrell et al., 1982) , as described previously (Gruetter et al., 1996a) . A 72 ml volume was selected to cover the occipital lobe based on FLASH imaging (TR=60ms, TE=7ms, 30 o flip angle). Data acquisition used a nominal DEPT editing pulse width θ of 90 o for maximal sensitivity of the glucose C1 through C5 resonances. Editing delays were set for a heteronuclear J CH coupling constant of 150Hz. Pulse widths and power were calibrated on an external small sphere placed at the 13 C coil center containing 13 C formic acid.
13 C pulse widths for a 180 o pulse were determined by nulling the formate signal at resonance and the 1 H pulse power for a 500 µs 90 o pulse were determined using the Bax method (Bax, 1983) . Pulse widths and power for the PRECISELY sequence were set according to the position relative to the coil based on previous calibrations. During acquisition (171 ms) WALTZ-16 decoupling was applied which resulted in a 5.6 % duty cycle (TR=3s) and an average power of less than 3 W, which is well within FDA guidelines.
Quantification of 13 C signals was performed using the external reference method as used in previous 13 C MRS studies of the human head (Gruetter et al., 1994b; Gruetter et al., 1992a; Gruetter et al., 1992b) and verified by comparison with chemical extraction (Gruetter et al., 1994a; Gruetter et al., 1991; Taylor et al., 1992) . Briefly, the effect of variable coil loading on sensitivity was assessed by measuring the fully relaxed signal of the formic acid sphere. The glucose signal was quantified by performing the identical experiment on a 4 liter phantom containing approximately 240mM natural abundance glucose:
This calculation assumes that the saturation factors of glucose are identical in vivo and in solution, both of which were assessed to be within 10% of each other based on the similarity of T 1 of creatine (Cr) and glucose in vivo and on the similar T 1 of glucose and creatine in solution. Signal differences due to differential T 2 were also neglected since the measured line width of 2-3Hz suggests T 2 is longer than 100 ms, which is much longer than the T 2 evolution time of the sequence (9ms).
Kinetic modeling
It has become widely accepted that the physical distribution space of glucose at steady-state equals the brain water phase, which implies that intra-and extracellular glucose are similar, i.e. that in the steady-state, glucose is evenly distributed in the brain's aqueous phase based on animal (Gjedde & Diemer, 1983; Lund-Andersen, 1979; Pappenheimer & Setchell, 1973) and on human studies (Gruetter et al., 1996c) . It has therefore become customary to assume a uniform brain glucose concentration past the blood-brain barrier, which is a foundation of the standard symmetric Michaelis-Menten model of brain glucose transport (Lund-Andersen, 1979) . The model further assumes that classical Michaelis-Menten kinetics are valid to describe the unidirectional fluxes across the lumenal and ablumenal membrane. It has also become customary to assume symmetric kinetic constants for influx and efflux across the blood-brain barrier. Furthermore it has been assumed that cerebral glucose consumption is constant at euglycemia and above, which is consistent with arteriovenous difference measurements and blood flow measurements in animals and humans (Boyle et al., 1994; Pappenheimer & Setchell, 1973) . We have shown that cerebral glucose at euglycemia is approximately 1µmol/g wet weight in the human brain (Gruetter et al., 1992a) , which is well above the K m of brain hexokinase (50µM), which further corroborated this assumption.
The standard Michaelis-Menten model was fitted to the measured steady-state brain glucose concentrations using the expression
The derivation of equations equivalent to Eq.
[3] has been subject of several papers and many previous studies (Gjedde & Christensen, 1984; Gjedde & Diemer, 1983; Gruetter et al., 1992a; Gruetter et al., 1993; Gruetter et al., 1996c; Mason et al., 1992; Pappenheimer & Setchell, 1973) . Brain glucose G brain is given in µmol/g and the metabolic rates T max , CMR glc are given in µmol/g min, whereas plasma glucose G plasma and the MichaelisMenten constant K t are given in mM. The physical distribution space of glucose was assumed at V d =0.77 ml/g (Gjedde & Diemer, 1983; Gruetter et al., 1996c; Holden et al., 1991) . It has been noted that including the endothelial compartment results in T max being replaced by T max *0.5 without changing the algebraic form of Eq.
[3], which may change the interpretation of T max to being the maximal transport rate across the endothelial cell membranes (Gjedde & Christensen, 1984; Mason et al., 1992; Pappenheimer & Setchell, 1973) . It is obvious from Eq. [3] that at saturating plasma glucose concentrations G brain approaches the upper limit of V d K t (T max /CMR glc -1).
Reversible Michaelis-Menten kinetics are applicable when the product formation is not unidirectional (Mahler & Cordes, 1971) . Such a situation is likely in vivo at metabolic steady-state and amounts to replacing the Michaelis-Menten constant K m by the term K m +P for product formation, and K m +S for the reverse reaction, conversely Mahler & Cordes, 1971) . This can be interpreted as reduced affinity for the forward reaction (influx) when substantial substrate (brain glucose) is present, a situation that would result in asymmetric kinetic properties.
As shown in the appendix, at steady-state the reversible Michaelis-Menten model results in the expression
which predicts that brain glucose is a linear function of plasma glucose when assuming a single membrane step. As shown in the appendix, including the endothelial compartment results in an algebraically identical expression that alters the value and interpretation of T max similar to the modification of the standard model. In addition, using asymmetric kinetic constants also preserves the linear relationship, and hence we conclude that a linear relationship between plasma and brain glucose is a general consequence of using the reversible formulation of Michaelis-Menten kinetics for the unidirectional transport rates.
Fitting of Eqs. 3 and 4 was performed using the Levenberg-Marquardt algorithm and the error analysis was performed by a Monte-Carlo simulation of noise using Gaussian deviates whose rms amplitude was set such that the average deviation was equal to that of the actual fit to the in vivo data (Press et al., 1989) . Statistical analysis was based on the covariance matrix provided by the fitting algorithm and the twodimensional scatter plot of simulated parameter pairs in parameter space, which was analyzed for covariance among the K t and T max /CMR glc and which was used to establish the statistically significant difference based on simulations using at least 2000 trial data sets. To account for a potential contribution of blood glucose present in the cerebral blood volume (CBV) to the overall glucose signal, the data was also fitted to Eqs. 3 and 4 plus the term CBV*G plasma . The effect of variable CBV was estimated by fitting G brain -CBV*G plasma to Eqs. 3 and 4 by systematically varying CBV between 0 and 0.075 ml/g.
RESULTS
All subjects were clamped at target glycemia for 20 minutes or more before spectroscopy was begun. Somatostatin infusion was tolerated well and suppressed endogenous insulin concentrations to below 5 µU/ml (30 pM). Qualitative ketone measurements were negative in all subjects. Proton MR spectra obtained from the occipital lobe at euglycemia and during a two-step hyperglycemic clamp are shown in Fig. 1A . The peak from the αH1 is clearly discernible at 5.23 ppm with at most a quadratically varying baseline due to residual water wings. Quantification of this signal was performed relative to the intensity of the creatine peak at 3.04 ppm obtained by Lorentzian fitting. The strong correlation of brain glucose with plasma glucose concentration is clearly evident by visual inspection of the data presented in Fig. 1A .
13 C MR spectra were obtained in three subjects during extended periods of hyperglycemia and a representative 13 C NMR spectrum is shown in Fig. 1B . Quantification of the 13 C NMR spectra was based on the external reference method, which gave a glucose concentration of 5.6 µmol/ml brain volume for this spectrum. It is interesting to compare the intensity of the 3β,5β peak at 76.6 ppm, which corresponds to 1.2 13 C concentration units with the peak of myo-inositol plus glucose at 72.0 ppm which corresponds to 2 or more 13 C concentration units. The former is approximately half the intensity of the latter peak at 72.0 ppm, providing a qualitative confirmation that the glucose concentration was approximately 6 µmol/ml brain vol, assuming identical relative sensitivity and a 7 µmol/ml vol myo-inositol concentration (Gruetter et al., 1992b; Kreis et al., 1993) .
The plot of the brain glucose concentrations measured as a function of plasma glucose is shown in Fig. 2 , where open squares indicate the concentrations derived by 1 H MRS. Brain glucose concentration is linearly correlated with plasma glucose as is indicated by the high correlation coefficient of 0.90 (n=27) which indicated an extremely high statistical significance for a linear relationship (p<0.001). Fitting a quadratic polynomial of the form a+bx+cx 2 gave a small c=-0.00178±0.0041, which is not different from zero (p>0.05). The plot of residuals of a linear regression is shown in Fig. 2C and confirms the impression that a line adequately describes brain glucose content. To validate the 1 H MRS quantification, we compared the cerebral glucose concentration measured by 1 H MRS to that determined by 13 C MRS. The concentrations derived by 1 H MRS gave a brain glucose concentration of 6.8±1.1mM (mean±SD) at 21.7±1.9mM in plasma (n=3), while the brain glucose concentration by natural abundance 13 C MRS was 6.9±0.9mM at 21.9±1.8mM plasma (n=3).
The fit of the present data to the standard symmetric Michaelis-Menten model of blood-brain glucose transport (Gjedde & Christensen, 1984; Gruetter et al., 1992a; Holden et al., 1991; Lund-Andersen, 1979; Mason et al., 1992) results the solid line in Fig. 2A and in K t =9.0±2.4 mM and T max /CMR glc =4.5±0.3 with a chi 2 =38. The errors were determined using a Monte- .44 ppm that rise concomitantly. The spectra were acquired at plasma glucose concentrations of 4.7 mM (bottom), 9.6 mM (middle) and 21 mM (top) indicated to the right of the respective spectrum and the corresponding quantification of the 5.23 ppm peak shown in the inset gave a brain glucose concentration of 1.2 mmol/g (bottom), 2.4 mmol/g (middle) and 5.5 mmol/g (top). B: The top spectrum shows a natural abundance spectrum acquired for 60 min from a 72 ml volume. The glucose resonances at 76.6 and 70.5 ppm were quantified by comparison with a phantom spectrum acquired at the same location under identical experimental parameters (bottom). Resonance assignments (Abbreviations: Glc -glucose; Gluglutamate; Gln -glutamine; Cr -creatine; Cho -choline groups; NAA -N-acetyl-aspartate) are based on estimated concentration and chemical shift (Willker et al., 1996) . Spectra were processed with a mild Lorentz to Gauss apodization (3Hz) and are shown without baseline correction. The shaded area represents the 95% confidence interval of extrapolated steady-state cerebral glucose concentrations calculated from previously published data using Eq. 3 and the kinetic parameters Kt=4.9±0.8mM, Tmax/CMRglc=3.56±0.2 (Gruetter et al., 1992a; Gruetter et al., 1993) . B: data from this study (l) and from the previous 13 C MRS study (m). The corresponding best fit of the reversible Michaelis-Menten model using Equation [4] to the solid circles is the solid line whereas the dotted line is the best fit of Eq. [4] to the open circles. The resulting fit parameters are given in Carlo simulation with a 1.15 mM root-mean-square noise level. Assuming the accepted standard for gray matter glucose consumption CMR glc of 0.3µmol g -1 min -1 (Heiss et al., 1984) , these kinetic constants yield a maximal transport rate T max of 1.3±0.1 µmol g -1 min -1 , which is 25 % above the previously reported values (Gjedde, 1992; Gruetter et al., 1996c) (Table 1) . Inspection of the generated two-dimensional MonteCarlo scatter plots spanning the parameter space showed that this set of kinetic constants is significantly different from that previously published (Gruetter et al., 1992a) , p<0.01.
Furthermore, the covariance of the two parameters was 0.28 for the previous study and -0.42 for the present study (p>0.05). Visual inspection of the parameter space confirmed the absence of any strong covariance. Moreover, all the glucose concentrations measured at plasma glucose above 20mM were significantly above 5 µmol/g. Brain glucose concentration was 8.6 µmol/g at 28.3 mM plasma glucose concentration which implies that at 30mM, the brain glucose concentration approaches 9 µmol/g (Fig.  2) . The shaded area in Fig. 2A shows the 95% confidence area of the predicted relationship between plasma and brain glucose based on the kinetic constants calculated in previous 13 C MRS studies of glucose transport in the human brain (Gruetter et al., 1992a; Gruetter et al., 1993) , see also row 6 in Table 1 . The 95% confidence area was determined from the extreme brain glucose concentrations calculated over the previously reported 95% confidence intervals of K t and T max /CMR glc . These previously reported constants were consistent with the average constants derived in positron emission tomography (PET) studies (Gjedde, 1992) in which the standard symmetric Michaelis-Menten model of brain glucose transport was also used (Table 1) . Despite the observed differences between the current and the extrapolated curve based on previously published kinetic constants, the experimental data presented in this study are in excellent agreement with these previous studies, all of which were measured at plasma glucose concentrations between 5 and 15mM. The agreement is further illustrated by the overlap between the shaded area and the present measurements ( Figure 2A, open squares) .
The measurement of brain glucose concentrations substantially above the K m of GLUT-1 in the human brain indicates that the E+P->EP reaction may proceed at significant rates and that glucose binding at the ablumenal membrane may partially inhibit the unidirectional influx. To evaluate whether incorporating such a mechanism can accommodate these measurements more consistently, we fitted the reversible Michaelis-Menten model using Eq [4] which resulted in K t =0.6±2.0 mM and T max /CMR glc =2.3±0.2. The resulting parameters are shown in Table 2 and the corresponding best fit (solid line) is shown in Fig. 2B . The residuals of this best fit (a line by definition) are shown in Fig. 2C and they indicate the absence of any trend in the residuals. To determine whether the previous 13 C MRS quantification can predict the high brain glucose values observed when using the reversible model, we fitted Eq. [4] also to the data reported in which are replotted in Fig. 2B (open circles) . Unlike the case with the symmetric (irreversible) Michaelis-Menten kinetic model, however, when Eq. 4 was fitted to the previously reported 13 C MRS quantification, the dashed line in Fig. 2B was obtained which is a much better extrapolation of brain glucose values to the present study than that achieved from the standard model (dashed curve in Fig. 2A ). The parameters of this fit are given in Table 2 .
To assess the influence of neglecting a vascular signal component to the MR signal of brain glucose we varied the cerebral blood volume (CBV) in the fit of Eq. 3 and 4. The resulting parameters are shown in Table 3 . The effect of progressively increasing the contribution of vascular signal to the MR signal was to produce a modest decrease in K t and T max in the fit of either model of blood-brain barrier transport . Linear regression analysis (bottom row) revealed that either parameter increased by 2% per 0.01 ml/g of underestimated blood volume. (Brooks et al., 1986) PET 4 3.9-5.7 4.2 0.4 -28% (Feinendegen et al., 1986) PET 6 2.7-7.7 3.8 2.0 272% (Gutniak et al., 1990) PET 8 2.7-6.0 4.1 a 0.5 a -23% (Blomqvist et al., 1991) PET 8 2.7-6.0 4.1 0.6 8% (Gruetter et al., 1992a) NMR 7 4.8-13 4.8 1.1 83% (Gruetter et al., 1996c) NMR 5 4.8-19 4.9 1.0 65% Present paper NMR 23 4.6-30 9.0 1.3 48% a Derived by fitting k 1 =T max /(K t +G plasma ) to k 1 measured at two different G plasma .
DISCUSSION
In this investigation, we have measured cerebral glucose concentrations under controlled conditions at levels of glycemia never before studied in healthy human subjects. The present measurements of cerebral glucose were found to be in excellent agreement over the same ranges of moderate hyperglycemia employed in previous studies. Our data was obtained by proton spectroscopy and confirmed by 13 C MRS. We found that a linear relationship exists between plasma and brain glucose concentrations over the range of plasma glucose used in this study, i.e. 4-30 mM. This linearity is directly illustrated in Fig. 1A , where the brain glucose signal increases in parallel with plasma glucose. Certainly that data, as well as the plots in Fig. 2 do not provide any evidence for an asymptotic upper limit of brain glucose between 4 and 30 mM plasma glucose, as required by the standard model. Further insight that a linear relationship describes brain glucose content is provided by fitting the standard model to the data points projected onto the linear regression curve, which assumes zero noise. The fit provided K t =4.8 and T max /CMR glc =3.63 for the previous 13 C data and K t =8.9 and T max /CMR glc =4.5 for the present study. These parameters are almost identical to those reported from the fit to the actual data reported above and mathematically reflect that the standard model attempts to mimic linear data acquired over a finite range of glycemia. Therefore, if a plateau exists as the standard model would predict, it is at a plasma glucose level well above 30mM which is at least an order of magnitude above the apparent K m reported for the erythrocyte carrier protein GLUT-1. We therefore conclude that the failure to extrapolate from a lower range of plasma glucose measured does not stem from the underestimation of a very high K m of glucose transport. Therefore, the only instance where the standard model is compatible with a linear relationship is when metabolism, CMR glc , is negligible compared to transport, T max . In such a situation brain glucose concentration would equal plasma glucose concentration, a condition which is clearly not present in normal brain. The observation of a linear relationship implies that many models previously used to describe the kinetics of cerebral glucose transport may not be adequate. Our data were best fit by a reversible Michaelis-Menten model where product formation is not a unidirectional process. Therefore, we conclude that cerebral glucose concentration may have a direct effect on the rate of unidirectional glucose uptake into the human brain.
The measurement of cerebral glucose by MRS is a direct, non-invasive approach that measures average tissue content of the metabolite. Even though we have taken great care that the signal was selected from a volume element that did not include any major veins, some contribution of the signal in smaller microscopic vessels can not be ruled out. However, based on the simulations presented in Table 4 , the assumption that 5% of cerebral volume is occupied by blood decreases the derived kinetic parameters by at most 10% and does not change the observed linearity of the blood-brain glucose relationship. It should also be noted that the present pulse sequence uses strong crusher gradients and induces some diffusion and perfusion weighting. Based on published measurements of attenuation of blood signal using 19 F MRS of fluorinated compounds in blood, the present b value of [4] to the data reported in (Gruetter et al., 1992a; Gruetter et al., 1993) . 54s/mm 2 is expected to attenuate the blood signal by approximately 40% (Neil et al., 1994) . Assuming that glucose in blood has a similar sensitivity to gradient dephasing as water, including the vascular signal decreases the kinetic constants by at most 6% , which is well within the experimental uncertainty of the present study.
Kinetic models of steady-state blood-brain barrier glucose transport have been based on two models (Fig.  3 ). The simpler model neglects the endothelial cell compartment (Fig. 3A) and requires two unidirectional fluxes T in and T out , which are traditionally modeled using standard Michaelis-Menten kinetics. The more general model (Fig. 3B ) includes effect of a very small, but finite endothelial cell compartment with negligible metabolism and with concomitant four unidirectional fluxes T (i) . Traditionally symmetric kinetic constants on both sides of the membrane are assumed. We show in the appendix that inclusion of the endothelial compartment yields also expressions algebraically equivalent to Eq. [4] (see appendix for the derivation of reversible kinetics). However, a difference exists relative to the analogous expressions for the standard model (Gjedde & Christensen, 1984; Mason et al., 1992; Pappenheimer & Setchell, 1973) , since the intercept as well as the slope are affected whether the endothelial cells are explicitly modeled, as can be seen by comparing Eq. A10 with Eq. A5. Recalculating the kinetic parameters using Eq. [A10] gave T max /CMR glc =4.4 and K t =0.5 mM. The relative transport rate thus is doubled which can be interpreted as representing the transport capacity across one endothelial membrane as in the case for the standard model. Note that K t is only minimally affected.
The linear relationship between plasma glucose and brain glucose is a robust feature of our brain glucose quantification since neither potential quantification errors nor a vascular contribution to the signal alter the linearity of the curve (Fig.  2) or any of the model assumptions.
The present observation of a linear brain glucose curve is consistent with earlier reports suggesting the presence of a high-affinity low-capacity transport system (Gjedde, 1981) or a non-saturable transport mechanism (Pardridge, 1983) , since both mechanisms give rise to a linear relationship as well. Therefore we cannot, based on our measurements, exclude the presence of such a mechanism although it remains to be determined how using the reversible Michaelis-Menten kinetic formulation may affect interpretation of tracer passage and extraction measurements, and whether the increase with plasma glucose concentration of the apparent K t in the reversible model would be sufficient to explain these previous observations, since the apparent K m for unidirectional influx is equal to the sum of K t and G brain . It is interesting to note that a similar analysis of kinetic tracer experiments in rat brain suggested that the difference of the two models may manifest itself as such a non-saturable component (Cunningham, 1986) .
The present study is in agreement with previous measurements of brain glucose in animal brain using standard kinetics, as can be seen by visual inspection of graphs provided in (Gjedde & Christensen, 1984) and in (Mason et al., 1992) , as well as in (Holden et al., 1991) , which reported a K t of 9-14 mM using the standard model, a value that is in excellent agreement with the present fit using the standard model (Table 2) . It is interesting to note that these studies measured a K t that is markedly higher than the K m measured in erythrocyte model systems against a zero intracellular glucose concentration (Carruthers, 1990) . A similar analysis of tracer kinetic data reported also millimolar K t in rat brain , but a different study suggested that when analyzing brain glucose as a function of plasma glucose using the standard model gave a K t of 14 mM in rat brain (Mason et al., 1992) . Such a high K t can be taken as an indication of an almost linear brain-blood glucose relationship.
Some studies have suggested that while the human GLUT-1 has anomalous asymmetric kinetic properties, most mammalian erythrocyte kinetics are symmetric (Cloherty et al., 1996) . Nevertheless, we show in the appendix that the linear relationship between brain and plasma glucose using reversible Michaelis-Menten kinetics is preserved even when assuming asymmetric kinetic properties. Since the model is thus underdetermined and most evidence suggests transport symmetry, e.g. (Gjedde & Diemer, 1983) , we assumed the transporter to be symmetric and refer to the derived kinetic constants as apparent constants of transport, K t and T max .
The present modeling of glucose transport includes reversible kinetics, i.e. adds the reverse reaction E+P→EP, which substantially reduces the intrinsic K t of glucose Fig. 3 Model of reversible Michaelis-Menten kinetics. The steadystate model assumes that past the blood-brain barrier, glucose is evenly distributed in the brain's aqueous phase (Gjedde & Diemer, 1983; Holden et al., 1991; Lund-Andersen, 1979; Mason et al., 1992) and that glucose consumption CMRglc is unaffected by changes in plasma glucose concentration over the range of glycemia studied. The model in A neglects the effect of the endothelial cell compartment, which is accounted for in model B. The unidirectional transport rates T are modeled assuming reversible Michaelis-Menten kinetics, given by expressions analogous to Eq.
[4].
transport since increased product concentration decreases the apparent affinity for substrate binding. Such a behavior is expected for the glucose transporter GLUT-1, since it has been shown that cytochalasin B, which binds to the efflux binding site, increases the K i for maltose binding at the sugar influx site of the carrier (Carruthers & Helgerson, 1991) . Furthermore, by comparing our measurements of brain glucose over an extended range of plasma glucose with those previously reported over a much narrower plasma glucose range (Gruetter et al., 1992a) , we obtained apparent MichaelisMenten constants T max , K t that are in excellent agreement and thus appear to be independent of the range of glucose levels studied. We finally note that the glucose transporter abundant at the blood-brain barrier and in the human erythrocyte have been ascribed to the same transporter phenotype, i.e. the ubiquitous GLUT-1 . In studies of erythrocyte model systems the Michaelis-Menten constant has been measured to be 0.5-2.0 mM against a zero glucose concentration inside (Carruthers, 1990) , which is in excellent agreement with the present study.
The maximum net glucose transport capacity across the blood-brain barrier at euglyemia can be estimated from the measured kinetic constants. Net glucose transport into the brain is maximal when brain glucose G brain falls into the range of the K m of hexokinase, which is approximately 50µM. The sustainable maximal glucose metabolic rate CMR glc is in this case determined by the unidirectional influx, and the relative increase that is possible in excess of basal CMR glc is given in the last column of Table 1 . The maximum sustainable rate of glucose uptake was calculated from max. T in = T max G plasma K t +G plasma (5) which is valid for both types of Michaelis-Menten kinetics discussed in this paper, as can be seen from Eq. A3 in the appendix and the well known formulations for the standard model (Gjedde, 1992; Gruetter et al., 1996c; Lund-Andersen, 1979; Pardridge, 1983) . It is interesting to note that the high K t of 9mM implies that the maximum net glucose transport capacity at the blood-brain barrier is 48% above the resting glucose consumption, which is similar to the glucose consumption rate measured during photic stimulation (Fox et al., 1988) . The low K t of approximately 1mM derived by fitting the reversible Michaelis-Menten kinetic model implies that the maximum glucose transport capacity is close to T max for most physiological plasma glucose concentrations in humans. At euglycemia the maximum sustainable metabolic rate of glucose is 71% or 94 % in excess of the basal rate of glucose combustion, as can be calculated from Table 2  using Equation 5 . These values easily accommodate most measured increases of CMR glc under physiological stimulation in the human occipital lobe, where the present study has been performed.
We conclude that the similarity of in vivo kinetic parameters with in vitro kinetic constants of GLUT-1 support the observation that the abundant cerebral glucose transporter at the blood-brain barrier is GLUT-1. Based on the quantification provided by proton and 13 C spectroscopy in this study and their excellent agreement with an independent study previously reported (Gruetter et al., 1992a) , the reversible Michaelis-Menten model describes steady-state brain glucose concentrations in the human brain consistently and allows for a transport capacity that is well in excess of observed physiological increases in cerebral metabolism.
